Nicox SA announced that the New Drug Application for approval to commercialize ZERVIATE®, 0.24%, submitted in China by its exclusive Chinese partner, Ocumension Therapeutics, has been included in the priority review and approval process of National Medical Products Administration of the People’s Republic of China.
